Insiders · GRTX

Mark Bachleda

Officer at Galera Therapeutics, Inc. (GRTX) since October 2021

Mark Bachleda has filed 7 insider reports with the SEC since October 2021, as director at Lyell Immunopharma, Inc. (LYEL) and officer at Galera Therapeutics, Inc. (GRTX). The latest filing, on June 12, 2026, reports grant or award at Lyell Immunopharma, Inc. (LYEL).

Filings
7
Companies
2
Bought on market
None
Sold on market
None

Companies where Mark Bachleda is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Lyell Immunopharma, Inc. logo
LYEL
Lyell Immunopharma, Inc.
Directorsince June 2025$13.89Jun 12, 2026
Galera Therapeutics, Inc. logo
GRTX
Galera Therapeutics, Inc.
Officersince October 2021Mar 1, 2023

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Mark Bachleda with

Other insiders at the same companies

Questions about Mark Bachleda

What is Mark Bachleda's role at Galera Therapeutics, Inc.?
Mark Bachleda reports to the SEC as officer at Galera Therapeutics, Inc. (GRTX), according to the latest filing on March 1, 2023. Mark Bachleda has also filed as director at Lyell Immunopharma, Inc. (LYEL).
Has Mark Bachleda bought or sold stock recently?
No open-market purchases or sales by Mark Bachleda are on file. The filings report grant or award.
How do I get alerts when Mark Bachleda files?
Follow Mark Bachleda on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Mark Bachleda (SEC CIK 0001887762). Totals count each trade once, skipping amendments whose original is on file, from Oct 13, 2021 on. View on SEC EDGAR